Arterra Bioscience
ARBS.MI
Italian Stock Exchange3.30
EUR
-0.02
- -
Arterra Bioscience
ARBS.MI
(Italian Stock Exchange)
Recent
price
3.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Arterra Bioscience is a biotechnology company primarily engaged in the research, development, and production of innovative natural ingredients and solutions for various industrial sectors including cosmetics, nutraceuticals, and medical devices. Founded in 2004 and headquartered in Naples, Italy, Arterra specializes in high-value product categories such as in vitro plant cultures; extraction of bioactive molecules from plant cells and agricultural by-products; and filling finished products for cosmetics, nutraceuticals, and medical devices markets. The company employs advanced freeze-drying technology to produce stable raw materials that do not require preservatives, enabling scalability to meet growing market demands. Its in vitro plant culture platform includes growth chambers with controlled parameters for optimized biomass production, while the extraction process utilizes environmentally respectful methods including solvent extractions with food-grade bioethanol and ultrasonic techniques. Finished products undergo rigorous sterilization processes using γ-radiation to ensure quality and microbiological safety. Arterra operates mainly in Italy but serves global markets within the cosmetics, nutraceutical, and medical device sectors. Its product offerings include innovative active compounds used by major cosmetic brands through partnerships, notably with Intercos and the Vitalab joint venture, which distribute its compounds for skincare and makeup applications. In addition, Arterra is expanding its industrial application areas, with recent developments targeting haircare products following Intercos' acquisition of Cosmit. The company also pursues strategic collaborations in medical devices; a notable partnership initiated in 2021 with ADL Farmaceutica for the production and licensing of active compound blends to treat skin conditions such as acne, which led to a capital stake acquisition by Arterra in ADL. This represents a strategic diversification beyond cosmetics into medical and pharmaceutical fields. Recent major changes include expanded research and partnerships aimed at broadening its biotechnology applications in medical devices and agri-food sectors, along with increased production capacity investments to optimize processes and support scalability. Arterra continues to innovate with new enabling proprietary technologies, including a novel bacterial system for generating innovative compounds in medical devices and pharmaceuticals, reflecting a strategic emphasis on high-value, technologically advanced products. The company remains listed on the Euronext Growth Milan market since its IPO in 2019 and maintains a strong regional connection to Naples, leveraging local natural raw materials and scientific talent for its R&D efforts. Overall, Arterra Bioscience stands as a focused biotech entity delivering sustainable, high-value biotechnologies by combining advanced plant cell culture techniques, environmentally conscious extraction methods, and specialized product formulation to serve global cosmetic, nutraceutical, and medical device markets. Its ongoing developments in new industrial applications and medical collaborations signal a strategic evolution aimed at diversified growth and innovation within its core biotechnological competencies.